{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:54:39Z","timestamp":1768071279246,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41391-020-0256-9","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T15:05:45Z","timestamp":1594998345000},"page":"150-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PI-RADS score v.2 in predicting malignancy in patients undergoing 5\u03b1-reductase inhibitor therapy"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-2327","authenticated-orcid":false,"given":"V.","family":"Forte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. U.","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-4601","authenticated-orcid":false,"given":"R.","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"de Soccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sperandio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ciccariello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"256_CR1","unstructured":"Gravas S, Cornu JN, Gacci M, CC Gratzke, Herrmann TRW, Mamoulakis C, et al. EAU guidelines\u2014management of non-neurogenic male LUTS. 2019:Chapter 5.2.2;18."},{"key":"256_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.urology.2004.08.042","volume":"65","author":"KA Iczkowski","year":"2005","unstructured":"Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology. 2005;65:76\u201382. https:\/\/doi.org\/10.1016\/j.urology.2004.08.042.","journal-title":"Urology."},{"key":"256_CR3","first-page":"337","volume":"109","author":"SL Roznovanu","year":"2005","unstructured":"Roznovanu SL, R\u0103dulescu D, Novac C, Stolnicu S. The morphologic changes induced by hormone and radiation therapy on prostate carcinoma. Rev Med Chir Soc Med Nat Iasi. 2005;109:337\u201342.","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"256_CR4","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N. Engl J Med. 2010;362:1192\u2013202.","journal-title":"N. Engl J Med"},{"key":"256_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(11)61619-X","volume":"379","author":"NE Fleshner","year":"2012","unstructured":"Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double blind, placebo-controlled trial. Lancet. 2012;379:1103\u201311.","journal-title":"Lancet"},{"key":"256_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.eururo.2012.11.006","volume":"63","author":"F Schr\u00f6der","year":"2013","unstructured":"Schr\u00f6der F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, et al. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart after Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol. 2013;63:779\u201387.","journal-title":"Eur Urol"},{"key":"256_CR7","doi-asserted-by":"publisher","first-page":"E789","DOI":"10.5489\/cuaj.2332","volume":"8","author":"L Klotz","year":"2014","unstructured":"Klotz L, Nabid A, Higano C, Ryanm C, Kebabdjian M, Chin J. Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. Can Urol Assoc J. 2014;8:E789\u201394.","journal-title":"Can Urol Assoc J"},{"key":"256_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.juro.2006.11.095","volume":"177","author":"SL Marks","year":"2007","unstructured":"Marks SL, Roehrborn CG, Wolford E, Wilson TH. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. J Urol. 2007;177:1408\u201313.","journal-title":"J Urol"},{"key":"256_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cct.2012.10.003","volume":"34","author":"NL Robertson","year":"2013","unstructured":"Robertson NL, Moore CM, Ambler G, Bott SR, Freeman A, Gambarota G, et al. MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging. Contemp Clin Trials. 2013;34:80\u20139.","journal-title":"Contemp Clin Trials."},{"key":"256_CR10","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1007\/s00330-017-4858-0","volume":"27","author":"F Giganti","year":"2017","unstructured":"Giganti F, Moore CM, Robertson NL, McCartan N, Jameson C, Bott SRJ, et al. MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. Eur Radiol. 2017;27:4767\u201374.","journal-title":"Eur Radiol"},{"key":"256_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haideret MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76:340\u201351.","journal-title":"Eur Urol"},{"key":"256_CR12","first-page":"S31","volume":"6","author":"JC Nickel","year":"2004","unstructured":"Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6:S31\u20139.","journal-title":"Rev Urol"},{"key":"256_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.juro.2016.11.090","volume":"197","author":"CM Moore","year":"2017","unstructured":"Moore CM, Robertson LN, Jichi F, Damola A, Ambler G, Giganti F, et al. The effect of dutasteride on magnetic resonance imaging defined prostate cancer: MAPPED-A randomized, placebo controlled, double-blind clinical trial. J Urol. 2017;197:1006\u201313.","journal-title":"J Urol"},{"key":"256_CR14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.juro.2017.02.2424","volume":"197","author":"F Giganti","year":"2017","unstructured":"Giganti F, Gambarota G, Moore CM, Robertson NL, McCartan N, Jameson C, et al. Prostate cancer detection using quantitative T2 and T2 -weighted imaging: the effects of 5-alpha-reductase inhibitors in men on active surveillance. J Urol. 2017;197:1006\u201313.","journal-title":"J Urol"},{"key":"256_CR15","doi-asserted-by":"publisher","unstructured":"Starobinets O, Kurhanewicz J, Noworolski SM. Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5\u03b1-reductase inhibitor treated individuals as compared with an untreated cohort. NMR Biomed. 2017;30. https:\/\/doi.org\/10.1002\/nbm.3696.","DOI":"10.1002\/nbm.3696"},{"key":"256_CR16","doi-asserted-by":"crossref","unstructured":"Chung TH, Noworolski SM, Kurhanewicz J, Weinberg V, Roach Iii M. A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer. BJU Int. 2011;108:E164\u201370.","DOI":"10.1111\/j.1464-410X.2010.10061.x"},{"key":"256_CR17","doi-asserted-by":"publisher","unstructured":"Mannaerts CK, Maudy G, Verbeek JF, Engelbrecht MRW, Savci-Heijink DC, Jager GJ, et al. Prostate cancer risk assessment in biopsy-naive patients: the rotterdam prostate cancer risk calculator in multiparametric magnetic resonance imaging-transrectal ultrasound (TRUS) fusion biopsy and systematic TRUS Biopsy. Eur Urol Oncol. 2018;1:109\u201317. https:\/\/doi.org\/10.1016\/j.euo.2018.02.010.","DOI":"10.1016\/j.euo.2018.02.010"},{"key":"256_CR18","doi-asserted-by":"publisher","unstructured":"Maxeiner A, Kittner B, Blobel C, Wiemer L, Hofbauer SL, Fischer T, et al. Primary Magnetic Resonance Imaging\/Ultrasonography Fusion-Guided Biopsy of the Prostate. BJU Int. 2018;122:211\u20138. https:\/\/doi.org\/10.1111\/bju.14212.","DOI":"10.1111\/bju.14212"},{"key":"256_CR19","doi-asserted-by":"publisher","unstructured":"Sidana A, Watson MJ, George AK, Rastinehad AR, Vourganti S, Rais-Bahrami S, et al. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: multi-institutional analysis. Urol Oncol. 2018;36:341. https:\/\/doi.org\/10.1016\/j.urolonc.2018.04.002.","DOI":"10.1016\/j.urolonc.2018.04.002"},{"key":"256_CR20","unstructured":"Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. 2019:Chapter 5.2;20."}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0256-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0256-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-020-0256-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:35:08Z","timestamp":1684618508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-020-0256-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1038\/s41391-020-0256-9","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]},"assertion":[{"value":"8 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}